Similar to cyclosporine, a potent new immunosuppressive agent, FK506, has been introduced in the management of severe uveitis. [22] This agent has been tried in a very limited
number of patients with uveitis, and further studies are required to evaluate the indications and contraindications of its use, and the use of other such potent immunosuppressive
agent.

  Nsaid  

Nonsteroidal anti-inflammatory drugs exert their effects by interfering with prostaglandin synthesis. While these drugs appear to have some role in the treatment of aphakic
cystoid macular oedema and certain types of scleritis, they generally have been found to be of little value in the treatment of most uveitis entities. However, experimental studies
 
do suggest that, specific lipoxygenase inhibitors may be useful in granulomatous uveitis [23] The lipoxygenase inhibitors are not yet available for clinical use, but once such
agents become available, they may be found to be effective in the management of granulomatous uveitis.

  Vitreous surgery  

There have been cases in which core vitrectomy in uveitis has altered the course of the disease. This beneficial effect was seen in some patients with intermediate uveitis and in
others with chronic uveitis associated with vitritis. Vitreous surgery is usually reserved for cases that fail to respond to systemic corticosteroids. For example, we employ the
following stepladder approach in the management of intermediate uveitis [Figure - 3]. These patients are treated initially with sub-Tenon's deposteroid injections for at least four
to six injections weekly or bimonthly. If there is no response to this therapy, we recommend systemic oral corticosteroids in the dose range of 40 to 60 mg /day. This therapy is
then continued for at least six to 12 weeks. If there is no response at the end of 12 weeks, the patient undergoes either pars plana vitrectomy or cryotherapy of the pars plana,
 
as described by Aaberg and associates [24] There are potential complications with both of these procedures, and these should be discussed with the patient prior to surgical
intervention. Following vitrectomy, some patients show improvement in the intraocular inflammation. Others may not show improvement from the surgical procedure, but may
respond well to sub-Tenon's injections of steroids or to oral prednisone therapy to which they were refractory prior to pars plana vitrectomy. There is a third group of patients
who do not show any beneficial effects from the surgery or from surgery plus steroid therapy, and it is these patients who are usually managed by cytotoxic/immunosuppressive
agents.